[
  {
    "ts": null,
    "headline": "REGN or ILMN: Which Is the Better Value Stock Right Now?",
    "summary": "REGN vs. ILMN: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=69abce10d4eca528de2aa9d9065be4d5b0e95b96160d2d4041adba4a8992910e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769186404,
      "headline": "REGN or ILMN: Which Is the Better Value Stock Right Now?",
      "id": 138228580,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "REGN vs. ILMN: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=69abce10d4eca528de2aa9d9065be4d5b0e95b96160d2d4041adba4a8992910e"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026",
    "summary": "Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026",
    "url": "https://finnhub.io/api/news?id=9c2e19ee826d2b499798ff6c3275f7b38ea8efdd9f055450e24e9d3ef2659780",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769181917,
      "headline": "Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026",
      "id": 138228964,
      "image": "",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=9c2e19ee826d2b499798ff6c3275f7b38ea8efdd9f055450e24e9d3ef2659780"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?",
    "summary": "Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=13e14c05b70229377a3e27632ac8f860511dc53939e6bd72c314cb476e1e183a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769180405,
      "headline": "Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?",
      "id": 138227077,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=13e14c05b70229377a3e27632ac8f860511dc53939e6bd72c314cb476e1e183a"
    }
  },
  {
    "ts": null,
    "headline": "How Regeneron’s Broader Biologics Pipeline And Capital Return Focus At Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story",
    "summary": "Regeneron Pharmaceuticals has recently drawn renewed attention as investment funds, Wall Street analysts, and industry observers highlight its broad biologics pipeline, disciplined capital allocation, and avoidance of large acquisitions, alongside ongoing initiatives such as its long-term US$100 million sponsorship of the Regeneron Science Talent Search. What stands out is how investors increasingly emphasize the value of Regeneron’s pipeline beyond flagship products, viewing its focus on...",
    "url": "https://finnhub.io/api/news?id=1ea59578ffbbd2c76c2c237d7b7b75d6b4ccd278d71b5a0fa067b25093c29501",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769163163,
      "headline": "How Regeneron’s Broader Biologics Pipeline And Capital Return Focus At Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story",
      "id": 138223505,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals has recently drawn renewed attention as investment funds, Wall Street analysts, and industry observers highlight its broad biologics pipeline, disciplined capital allocation, and avoidance of large acquisitions, alongside ongoing initiatives such as its long-term US$100 million sponsorship of the Regeneron Science Talent Search. What stands out is how investors increasingly emphasize the value of Regeneron’s pipeline beyond flagship products, viewing its focus on...",
      "url": "https://finnhub.io/api/news?id=1ea59578ffbbd2c76c2c237d7b7b75d6b4ccd278d71b5a0fa067b25093c29501"
    }
  }
]